Skip to main content
Top
Published in: Clinical Rheumatology 3/2024

12-02-2024 | Systemic Lupus Erythematosus | ORIGINAL ARTICLE

Classifying systemic lupus erythematosus using laboratory items alone: a preliminary study

Authors: Lin Zhang, Jinlu Ma, Dong Yan, Zhichun Liu, Leixi Xue

Published in: Clinical Rheumatology | Issue 3/2024

Login to get access

Abstract

Objectives

To explore the performance of laboratory items alone in systemic lupus erythematosus (SLE) classification.

Methods

Our cohort consisted of 352 and 385 (control) patients with and without SLE. This study evaluated the performance of the American College of Rheumatology (ACR)-1997, Systemic Lupus International Collaborating Clinics (SLICC)-2012, European League Against Rheumatism (EULAR)/ACR-2019, and Systemic Lupus Erythematosus Risk Probability Index (SLERPI) using laboratory items alone, including blood and urine test results.

Results

The median ratio of laboratory items/total items was 66.7%, 75.0%, 60.4%, and 77.4% in ACR-1997, SLICC-2012, EULAR/ACR-2019, and SLERPI, respectively. After including laboratory items alone, the sensitivity of ACR-1997, SLICC-2012, EULAR/ACR-2019, and SLERPI was 31.3% (95% confidence interval [CI]: 26.4%–36.4%), 79.8% (95% CI: 75.3%–83.9%), 75.9% (95% CI: 71.0%–80.2%), and 85.2% (95% CI: 81.1%–88.8%), respectively. We referenced the SLERPI and removed the additional restrictions, i.e., SLICC-2012 criteria only needs to fulfill at least four items (mSLICC-2012) and EULAR/ACR-2019 criteria needs to have ≥ 10 points (mEULAR/ACR-2019) to qualify for SLE classification. The mSLICC-2012 and mEULAR/ACR-2019 criteria, including laboratory items alone, newly identified 13 and 25 patients, respectively. Based on laboratory items alone, the combination of mSLICC-2012, mEULAR/ACR-2019, and SLERPI identified 348 patients with an improved sensitivity of 90.6% (95% CI: 87.1%–93.5%). Patients, who were classified according to the mEULAR/ACR-2019 criteria, all met the other criteria.

Conclusion

Incorporating laboratory items alone was clinically feasible to help identify SLE. SLERPI and SLICC-2012, using laboratory items alone, were more worthwhile to promote in the clinic compared with EULAR/ACR-2019.
Key Points
• Laboratory items play a crucial role in the SLE classification criteria, and incorporating laboratory items alone was clinically feasible to help in the identification of SLE.
• The SLERPI and SLICC-2012, using laboratory items alone, were more worthwhile to promote in the clinic compared with EULAR/ACR-2019, and the combination of the two could further improve the sensitivity.
• The relative simplicity of evaluating laboratory indices may help nonrheumatologists and inexperienced rheumatologists to identify SLE more quickly, thereby reducing the risk of delayed diagnosis in patients.
Literature
21.
go back to reference Adamichou C, Nikolopoulos D, Genitsaridi I et al (2020) In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis 79(2):232–241. https://doi.org/10.1136/annrheumdis-2019-216155CrossRefPubMed Adamichou C, Nikolopoulos D, Genitsaridi I et al (2020) In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis 79(2):232–241. https://​doi.​org/​10.​1136/​annrheumdis-2019-216155CrossRefPubMed
Metadata
Title
Classifying systemic lupus erythematosus using laboratory items alone: a preliminary study
Authors
Lin Zhang
Jinlu Ma
Dong Yan
Zhichun Liu
Leixi Xue
Publication date
12-02-2024
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 3/2024
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-024-06893-9

Other articles of this Issue 3/2024

Clinical Rheumatology 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine